Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option
Published: February 05, 2026 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)'s Wegovy. The oral treatment uses the same active ingredient as Wegovy but is formulated to improve digestion and absorption, eliminating the need for injections.
Read More
Novo Nordisk CEO: Hims' $49 compounded Wegovy pill a 'waste' of money
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers Health was launching a cut-price version of Novo's blockbuster Wegovy weight loss pill.
Read More
Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an introductory price of $49 per month.
Read More
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
Published: February 05, 2026 by: Market Watch
Sentiment: Positive
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Read More
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Published: February 05, 2026 by: CNBC
Sentiment: Negative
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Read More
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Published: February 04, 2026 by: The Motley Fool
Sentiment: Neutral
Hims & Hers is moving beyond prescriptions to preventative testing.
Read More
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $26.44, indicating a -2.4% shift from the previous trading day.
Read More
Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Published: February 02, 2026 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international pa.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers: A Platform Strategy Pivot Driving Long-Term Value
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Positive
While the market fixates on short-term product cycles, Hims & Hers (HIMS) is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. The introduction of "Labs" creates the data layer for continuous health optimization, deepening engagement and enabling increasingly precise, personalized care over time. Scale achieved from making healthcare accessible to millions helps the company drive down unit costs, lower prices, expand adoption, and create a self-reinforcing flywheel of growing reach, engagement, and long-term platform value.
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Telehealth Stock Popular With Bulls Despite Underperformance
Published: January 26, 2026 by: Schaeffers Research
Sentiment: Positive
Hims & Hers Health Inc (NYSE:HIMS) shares are up 3.4% to trade at $30.60 at last glance.
Read More
Hims & Hers Scales Platform-Led Digital Healthcare Access and Care
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care platform with new diagnostics, AI tools and specialty treatments for personalized health.
Read More
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Read More
Hims & Hers Expands Platform-Led Access to Digital Healthcare
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS leverages a software-driven platform to scale personalized digital care across new health categories and markets.
Read More
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers Expands Platform-Led Access to Provider-Directed Care
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.
Read More
Hims & Hers Health: Capitalizing On Healthcare Innovation
Published: January 09, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substantial upside if it becomes more like AI/genomics companies but significant downside if risks materialize.
Read More
Hims & Hers Growth Story Has A Lot To Prove In 2026
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured Hims stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international expansion are promising, yet have not driven meaningful revenue acceleration.
Read More
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.
Read More
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integration, and a unique personalized offering position HIMS to regain historical growth rates by 2026 and beyond. Management targets substantial margin expansion, aiming for adjusted EBITDA margins of at least 20% by 2030, with marketing spend expected to decrease.
Read More
Hims & Hers Health: Under-Appreciated Upside
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is aggressively expanding through new product launches, international markets, and strategic acquisitions, supporting a bullish outlook. HIMS targets $6.5 billion in 2030 revenue, leveraging a subscriber base with significant runway to reach a 10 million target. Management signals potential to exceed long-term targets, reinforced by a $250 million share buyback reflecting confidence in undervalued shares.
Read More
Hims & Hers: A Rare GARP Setup After The Market Reset
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is an asset-light platform. Subscriptions, cross-selling, and personalization drive rising ARPU, strong retention, and improving unit economics with structurally low CAC. Growth has normalized but remains ~50%+, driven by weight loss, Hers, diagnostics, and international expansion. Focusing on personalized plans lifts ARPU and retention, improving revenue quality. Margin volatility reflects investments, not pricing pressure. EBITDA margins remain healthy, free cash flow is positive, marketing efficiency is improving, and liquidity exceeds $1.1 billion.
Read More
Hims & Hers: Capitalizing On Robust Subscriber/ARPU Growth - Upgraded Buy Rating
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international expansion through M&A activities, and strong operating leverage underpin HIMS' long-term revenue and EBITDA growth prospects. Regulatory headwinds from the FDA and new legislation pose near-term risks, but management remains confident in GLP-1 monetization and compliance.
Read More
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
Read More
Hims & Hers: A Great Moment To Buy The Dip
Published: January 05, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into new specialties and diagnostics, with international growth representing a $1 billion medium-term opportunity. Q3 revenue grew 49% y/y to $599 million, beating expectations, with subscriber growth and rising average revenue per subscriber driving strong fundamentals.
Read More
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
Read More
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
Published: December 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.
Read More
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637